3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase NA
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
Genitourinary
1
CNS
1
Conditions
Lymphoma
16
Lymphoma, Non-Hodgkin
11
Lymphoma, Large B-Cell, Diffuse
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Leukemia, Lymphocytic, Chronic, B-Cell
7
Hodgkin Disease
7
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, B-Cell, Marginal Zone
6
Leukemia, Myeloid, Acute
6
Lymphoma, Mantle-Cell
5
Lymphoma, Follicular
5
Small Cell Lung Carcinoma
4
Neuroblastoma
4
Burkitt Lymphoma
4
Testicular Neoplasms
3
Sarcoma
3
Lymphoma, T-Cell
3
Leukemia
3
Central Nervous System Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Waldenstrom Macroglobulinemia
2
Testicular Germ Cell Tumor
2
Teratoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Osteosarcoma
2
Neoplasms, Germ Cell and Embryonal
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Interventions
Cisplatin
8
Etoposide
6
Paclitaxel
5
Ifosfamide
4
Sunitinib
3
Oxaliplatin
3
Cyclophosphamide
3
Brentuximab Vedotin
3
tremelimumab
2
pembrolizumab
2
etoposide phosphate
2
durvalumab
2
Sirolimus
2
Gemcitabine
2
Everolimus
2
Epirubicin
2
Dexamethasone
2
Carboplatin
2
Bleomycin
2
Bevacizumab
2
tozuleristide
1
rolapitant
1
ribociclib
1
pegfilgrastim
1
pazopanib
1
olaparib
1
fosaprepitant
1
fludarabine phosphate
1
fludarabine
1
cabozantinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Germ Cell and Embryonal
×
etoposide phosphate
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled
NCT06309732
2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2
Completed
36 enrolled